|
Products |
| Products |
|
Diseases |  |
News |  |
| «12...5657585960616263646566...39323933» |
- | Campath (alemtuzumab) / Sanofi
Journal: Does a subset of mature T-cell leukemias with features akin to T-cell prolymphocytic leukemia but lacking rearrangement of the TCL1 represent peripheral T-cell lymphoma, NOS in a leukemic phase? (Pubmed Central) - Aug 19, 2024
We present a patient diagnosed with T-PLL with MTCP1 rearrangement who was successfully treated with alemtuzumab followed by consolidative allogeneic unrelated donor stem cell transplantation...However, the lymphoma cells were clonally related to those at presentation. Currently, literature on T-PLL-like cases lacking the rearrangement of TCL1A is limited, and the possibility of whether a proportion of such cases could represent PTCL, NOS (with leukemic involvement) needs consideration.
- | Tecvayli (teclistamab-cqyv) / Genmab, J&J
Journal: "Fast but not so furious": A condensed step-up dosing schedule of teclistamab for relapsed/refractory multiple myeloma. (Pubmed Central) - Aug 19, 2024
The schedule was found to be safe and reduced hospital length of stay. These results should prompt consideration of shorter hospital stays for patients who do not experience CRS and raise the possibility of outpatient administration with close observation.
- | Darzalex (daratumumab) / J&J
Journal: Dramatically elevated plasma vascular endothelial growth factor levels from influenza A infection in polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes syndrome: A case report. (Pubmed Central) - Aug 19, 2024
In hindsight, a concurrent influenza A infection was the likely driver of his VEGF elevation rather than his underlying POEMS syndrome. Given the importance of longitudinal VEGF monitoring and the infectious risks of plasma cell therapies, our case highlights the need for caution with POEMS response assessments in the setting of a respiratory viral infection.
- | methotrexate IV / Generic mfg., methotrexate / Generic mfg., cytarabine / Generic mfg.
Journal, Real-world evidence, Real-world: Sequential high-dose methotrexate and cytarabine administration improves outcomes in real-world patients with primary central nervous system lymphoma: A report from the Australasian Lymphoma Alliance. (Pubmed Central) - Aug 19, 2024
Given the importance of longitudinal VEGF monitoring and the infectious risks of plasma cell therapies, our case highlights the need for caution with POEMS response assessments in the setting of a respiratory viral infection. 190/204 (93%) patients (median age: 65) received one of five high-dose methotrexate (HD-MTX) containing chemotherapy regimens: MPV/Ara-C (HD-MTX, procarbazine, and vincristine, followed by cytarabine [Ara-C]) (n
- | Sarclisa (isatuximab-irfc) / Sanofi
Journal: Effective treatment of refractory monoclonal gammopathy-associated pure red cell aplasia with isatuximab, pomalidomide and dexamethasone. (Pubmed Central) - Aug 19, 2024
Monoclonal gammopathy-associated pure red cell aplasia (MG-PRCA) is characterized by the absence or pronounced hypoplasia of erythroid precursors in the bone marrow, causing reticulocytopenia and a normocytic, normochromic anaemia in a patient with a monoclonal plasma cell dyscrasia. We report here on the successful treatment of MG-PRCA with isatuximab, pomalidomide, and dexamethasone after multiple lines of immunosuppressive and anti-plasma cell-directed treatments.
- | Talvey (talquetamab-tgvs) / J&J
Journal: Weight loss and dysgeusia in relapsed/refractory multiple myeloma patients treated with talquetamab. (Pubmed Central) - Aug 19, 2024
Weight loss and dysgeusia are important adverse events to consider while on talquetamab treatment. Extending dose intervals can potentially prevent such adverse events and should be studied in future prospective clinical trials.
- || Rituxan (rituximab) / Roche
Review, Journal: Update on non-infectious uveitis treatment: anti-TNF-alpha and beyond. (Pubmed Central) - Aug 19, 2024
inhibitors, anti-CD20 therapy and alkylating agents have shown considerable efficacy. In this review, we delve into the latest evidence surrounding the effectiveness of biologic therapy and introduce novel therapeutic strategies targeting immune components as potential avenues for advancing treatment of NIU.
- | Inlyta (axitinib) / Pfizer, Tasigna (nilotinib) / Novartis, Inhibikase
Journal, IO biomarker: Epigenetic dysregulated long non-coding RNAs in renal cell carcinoma based on multi-omics data and their influence on target drugs sensibility. (Pubmed Central) - Aug 19, 2024
Further, biological enrichment and immuno-infiltration analysis was conducted to investigate the fundamental differences between patients categorized as high or low risk. Our research improves the understanding in the function of epigenetic dysregulated long non-coding RNAs in renal carcinoma.
- | Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche, Rituxan (rituximab) / Roche
Journal: Synchronous Invasive Ductal Carcinoma of Breast and Diffuse Large B-cell Lymphoma: A Case Report. (Pubmed Central) - Aug 19, 2024
She was given three cycles of rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisolone (R-CHOP) protocol...She was recommended weekly paclitaxel for 12 cycles and trastuzumab and pertuzumab for 1 year...Biopsy of metastatic sites should be done wherever possible. All histopathologies should be reviewed thoroughly before treatment initiation, as they may significantly alter patient management.
- || Rituxan (rituximab) / Roche
Clinical data, Journal, Combination therapy: Clinical Outcome of Patients Receiving Rituximab in Combination with Bendamustine in Indolent B-cell Lymphomas: A Single-center Institutional Study. (Pubmed Central) - Aug 19, 2024
Moreover, 76.1% had no disease progression for the first 2 years. It adds to the existing body of literature that demonstrates that in real-world experience, the outcomes of R-Benda treatment are better than those reported by earlier randomized-control trials.
- | tomivosertib (eFT508) / eFFECTOR Therap
Journal: Interleukin-6 induces nascent protein synthesis in human dorsal root ganglion nociceptors primarily via MNK-eIF4E signaling. (Pubmed Central) - Aug 19, 2024
To pinpoint the specific molecular mechanisms driving this IL-6-driven increase in nascent proteins, we used the specific MNK1/2 inhibitor eFT508...Our findings provide clear evidence that IL-6 drives nascent protein synthesis in human TRPV1+ nociceptors primarily via MNK1/2-eIF4E signaling. The work links animal findings to human nociception, creates a framework for additional hDRG signaling experiments, and substantiates the continued development of MNK inhibitors for pain.
- | Orencia (abatacept) / BMS
Journal: Risk factors for interstitial lung disease in rheumatoid arthritis: a cohort study from the KOBIO registry. (Pubmed Central) - Aug 19, 2024
The incidence of ILD was significantly higher in those taking tumor necrosis factor inhibitors and abatacept than in those taking csDMARDs (log ranked p?<?0.001)...ILD is a rare but critical extra-articular symptom of RA patients. Therefore, RA patients with the above risk factors should be monitored carefully for ILD development.
- | Rituxan (rituximab) / Roche
Journal: Severe Granulomatosis With Polyangiitis Treated With Low-Dose Cyclophosphamide, Rituximab, Glucocorticoids, and Plasma Exchange: A Case Report. (Pubmed Central) - Aug 19, 2024
A prompt diagnosis is necessary to initiate treatment and preserve organ function. More research is needed to determine which combination therapies are the best treatment modalities in cases of severe multi-organ system involvement.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal: A Case Report of Pembrolizumab-Induced Allergic Hepatitis. (Pubmed Central) - Aug 19, 2024
The lymphocyte transformation test was only positive for pembrolizumab. Clinicians should consider pembrolizumab-induced allergic hepatitis as a possible cause of liver injury after excluding liver metastasis and immune-related adverse events.
- | Journal, PARP Biomarker, PD(L)-1 Biomarker, Metastases: Use of Radiation Therapy for Ataxia-Telangiectasia Mutated (ATM)-Mutation Metastatic Renal Cell Carcinoma: A Case Report. (Pubmed Central) - Aug 19, 2024
After progression of disease (POD) on ipilimumab/nivolumab, followed by POD on cabozantinib, the patient was treated with radiation therapy to metastatic cervical lymphadenopathy to 60 Gy in 15 fractions as well as retroperitoneal lymphadenopathy to 36 Gy in 9 fractions, which was curtailed due to intolerance. This was followed by sequential systemic therapy with a poly (ADP-ribose) polymerase (PARP) inhibitor and pembrolizumab, which
- | Verzenio (abemaciclib) / Eli Lilly
Journal: Chronic Use of Abemaciclib Leading to Breathlessness and Demise: A Case Report. (Pubmed Central) - Aug 19, 2024
It is important, along the course of cancer treatment and goals of care discussion, to educate patients and their families on possible side effects of chemotherapy and involve specialists early with the goal of lowering mortality rates. Most patients do not survive this unfortunate progression of disease.
- || Rituxan (rituximab) / Roche
Review, Journal: Diagnostic and Therapeutic Strategies in Evans Syndrome: A Case Report and Literature Review. (Pubmed Central) - Aug 19, 2024
First-line treatments consist of corticosteroids and intravenous immunoglobulin; refractory cases may also require rituximab, thrombopoietin receptor antagonists, and sirolimus. Achieving remission and lowering relapse rates need careful patient monitoring and customized treatment programs.
- | Gazyva (obinutuzumab) / Roche, Biogen
Journal: Obinutuzumab as Initial or Second-Line Therapy in Patients With Primary Membranous Nephropathy. (Pubmed Central) - Aug 19, 2024
Obinutuzumab may represent a promising and well-tolerated therapeutic option for individuals with primary MN. The potential of Obinutuzumab was highlighted as an initial therapy for primary MN.
- || Orencia (abatacept) / BMS, Rituxan (rituximab) / Roche
Review, Journal: Potential of resveratrol in the treatment of systemic lupus erythematosus (Review). (Pubmed Central) - Aug 19, 2024
Recent evidence suggests that resveratrol (RSV) has the effect of ameliorating immune disorders by inhibiting overactivation of immune cells. In the present review, advances in research on the protective effects and potential mechanisms of RSV against SLE are summarized and the potential potency of RSV and its use as a promising therapeutic option for the treatment of SLE are highlighted.
- | Tedopi (OSE 2101) / OSE Immunotherapeutics, Keytruda (pembrolizumab) / Merck (MSD)
Journal: TEDOVA: vaccine OSE2101 +/- pembrolizumab as maintenance in platinum-sensitive recurrent ovarian cancer. (Pubmed Central) - Aug 19, 2024
P2
Patients in first or second platinum sensitive relapse after poly ADP-ribose polymerase inhibitors and bevacizumab represent an area of unmet medical need. This academic sponsored, international Phase II randomized trial is evaluating the combination of a therapeutic cancer vaccine (OSE2101) with anti-PD1 (pembrolizumab) as maintenance therapy, in patients with platinum-sensitive recurrence regardless of number of prior lines and no progression after platinum-based chemotherapy.Clinical Trial Registration: NCT04713514 (ClinicalTrials.gov).
- | Opdivo (nivolumab) / BMS
Journal, Metastases: Prognostic value of type of prior TKI in pretreated metastatic renal cell carcinoma patients receiving nivolumab. (Pubmed Central) - Aug 19, 2024
Moreover, no difference between sunitinib and pazopanib was found according to the International Metastatic RCC Database Consortium prognostic score. There is no conclusive evidence favoring pazopanib or sunitinib treatment before initiating nivolumab therapy in metastatic renal cell carcinoma patients.
- | Rituxan (rituximab) / Roche
Journal, Head-to-Head: Evaluating 64Cu-DOTA-rituximab as a PET agent in patients with B-cell lymphoma: a head-to-head comparison with 18F-fluorodeoxyglucose PET/computed tomography. (Pubmed Central) - Aug 19, 2024
The results of this study demonstrate the feasibility of using 64Cu-DOTA-rituximab PET/CT to evaluate the CD20 expression. The increased 64Cu-DOTA-rituximab uptake in lymph nodes associated with tumors, higher SUVmax, and tumor-to-muscle ratios observed with 64Cu-DOTA-rituximab PET/CT compared with 18F-FDG PET/CT, highlight the diagnostic potential of this imaging modality.
- | sunitinib / Generic mfg.
Journal: Sunitinib alleviates hepatic ischemia reperfusion injury by inhibiting the JAK2/STAT pathway and promoting the M2 polarization of macrophages. (Pubmed Central) - Aug 19, 2024
In IL-4-stimulated macrophages, application of C-A1 activated the JAK2/STAT pathway and decreased M2-type macrophages, which was reversed by Sunitinib treatment either. Sunitinib is capable of guiding the polarization of macrophages toward an M2-type phenotype via the inhibition of the JAK2/STAT pathway, thereby exerting a protective effect on hepatic IRI.
- | Blincyto (blinatumomab) / Astellas, Amgen
Journal: The characterization and the impact of CSF pleocytosis during blinatumomab therapy for adult acute lymphoblastic leukemia. (Pubmed Central) - Aug 19, 2024
Analysis of CSF by flow cytometry showed median CD4:CD8 ratio of 1.34. In conclusion, CSF pleocytosis is prevalent with blinatumomab but only demonstrated lower rates of non-CNS extramedullary relapse but no impact on CNS relapse or neurotoxicity.
- | Venclexta (venetoclax) / Roche, AbbVie, Rituxan (rituximab) / Roche
Journal: Successful treatment of acquired von Willebrand syndrome secondary to low-grade CLL with rituximab and venetoclax. (Pubmed Central) - Aug 19, 2024
In conclusion, CSF pleocytosis is prevalent with blinatumomab but only demonstrated lower rates of non-CNS extramedullary relapse but no impact on CNS relapse or neurotoxicity. No abstract available
- | Promacta (eltrombopag) / Novartis
Journal: Haematopoietic regeneration by HLA-A*0206-deficient clones in severe aplastic anaemia without definitive immunosuppressive treatment. (Pubmed Central) - Aug 19, 2024
Flow cytometry and deep nucleotide sequencing revealed that haematopoiesis was primarily supported by several clones with somatic mutations that inactivated antigen presentation via HLA-A*0206. This suggests that monitoring haematopoietic regeneration by immune escape clones could be an alternative approach for immune aplastic anaemia patients who possess HLA allele-deficient clones and cannot tolerate standard therapy.
- | Verzenio (abemaciclib) / Eli Lilly
Trial completion date, Trial primary completion date, Metastases: Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma (clinicaltrials.gov) - Aug 19, 2024
P2, N=18, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
This suggests that monitoring haematopoietic regeneration by immune escape clones could be an alternative approach for immune aplastic anaemia patients who possess HLA allele-deficient clones and cannot tolerate standard therapy. Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
- | Tecentriq (atezolizumab) / Roche
Enrollment closed: Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) (clinicaltrials.gov) - Aug 19, 2024
P2, N=38, Active, not recruiting, Sponsor: Fundaci
Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025 Recruiting --> Active, not recruiting
- | dexrazoxane / Generic mfg.
Enrollment open: HO170DLBCL: Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma (clinicaltrials.gov) - Aug 19, 2024
P3, N=324, Recruiting, Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || PF-08046054 / Pfizer
Enrollment change, Metastases: SGNPDL1V-001: A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors (clinicaltrials.gov) - Aug 19, 2024
P1, N=438, Recruiting, Sponsor: Seagen Inc.
Not yet recruiting --> Recruiting N=322 --> 438
- | Opdivo (nivolumab) / BMS
New P2 trial: Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions (clinicaltrials.gov) - Aug 19, 2024
P2, N=45, Not yet recruiting, Sponsor: M.D. Anderson Cancer Center
- | Elzonris (tagraxofusp-erzs) / Menarini
New P1/2 trial: Tagraxofusp and Low-Intensity Chemotherapy of CD123-Positive Relapsed or Refractory AML (clinicaltrials.gov) - Aug 19, 2024
P1/2, N=20, Not yet recruiting, Sponsor: Stanford University
- || Scemblix (asciminib) / Novartis
Enrollment open: Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 19, 2024
P2, N=40, Recruiting, Sponsor: M.D. Anderson Cancer Center
N=322 --> 438 Not yet recruiting --> Recruiting
- | Darzalex (daratumumab) / J&J
Enrollment open: FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM) (clinicaltrials.gov) - Aug 18, 2024
P3, N=599, Recruiting, Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Verzenio (abemaciclib) / Eli Lilly
Trial completion date, Trial primary completion date: BEAUTY: Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer (clinicaltrials.gov) - Aug 18, 2024
P2, N=200, Recruiting, Sponsor: Mayo Clinic
Not yet recruiting --> Recruiting Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025
- || PD-L1.t-haNK / ImmunityBio, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Phase classification, Trial completion date, Trial primary completion date, Checkpoint inhibition: QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors (clinicaltrials.gov) - Aug 18, 2024
P2, N=147, Active, not recruiting, Sponsor: ImmunityBio, Inc.
Trial completion date: Jul 2024 --> Jul 2025 | Trial primary completion date: Jul 2024 --> Jul 2025 Phase classification: P2b --> P2 | Trial completion date: Dec 2024 --> Dec 2030 | Trial primary completion date: May 2024 --> Aug 2029
- | CD19x22 CAR T / University of Colorado
New P1 trial, CAR T-Cell Therapy: CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL (clinicaltrials.gov) - Aug 18, 2024
P1, N=26, Not yet recruiting, Sponsor: University of Colorado, Denver
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial completion date, Trial primary completion date, Combination therapy: AALL1731: A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (clinicaltrials.gov) - Aug 18, 2024
P3, N=6720, Suspended, Sponsor: National Cancer Institute (NCI)
Phase classification: P2b --> P2 | Trial completion date: Dec 2024 --> Dec 2030 | Trial primary completion date: May 2024 --> Aug 2029 Trial completion date: Jun 2029 --> Sep 2027 | Trial primary completion date: Jun 2029 --> Sep 2027
- || Opdivo (nivolumab) / BMS, Jeselhy (pimitespib) / Otsuka
Review, Journal, PD(L)-1 Biomarker, IO biomarker: An update on the status of HSP90 inhibitors in cancer clinical trials. (Pubmed Central) - Aug 18, 2024
Our focus lies in evaluating drug efficacy, prognosis forecast, pharmacodynamic biomarkers, and clinical outcomes reported in published trials. Through this comprehensive review, we aim to shed light on the progress and potential of HSP90 inhibitors as promising therapeutic agents in cancer treatment.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal, Real-world evidence, Real-world, Metastases: Treatment selection and real-world analysis of immunotherapy with or without chemotherapy in PD-L1-high metastatic non-small cell lung cancer. (Pubmed Central) - Aug 18, 2024
Limitations include small sample size and data cut-off. Future prospective studies could incorporate comorbid status and a validated disease burden score to stratify patients.
- | Tysabri (natalizumab) / Biogen, Royalty, Ocrevus (ocrelizumab) / Roche
Journal: A comparison of natalizumab and ocrelizumab on disease progression in multiple sclerosis. (Pubmed Central) - Aug 17, 2024
Future prospective studies could incorporate comorbid status and a validated disease burden score to stratify patients. Both medications strongly suppress RAW events and, in the short term, the risk of achieving PIRA events, EDSS 4.0 and 6.0 milestones is not significantly different.
- || Opdivo (nivolumab) / BMS
Biomarker, Clinical, Journal, Monotherapy, Metastases: Prognostic factors of second-line nivolumab monotherapy for unresectable or metastatic esophageal cancer: a multi-institutional cohort study for 184 cases. (Pubmed Central) - Aug 17, 2024
Furthermore, a good performance status and low C-reactive protein levels may identify patients who are likely to benefit from therapy. Third-line chemotherapy after nivolumab treatment may have an enhanced effect; however, further prospective studies are required to confirm this finding.
- | Tecartus (brexucabtagene autoleucel) / Gilead
Journal, CAR T-Cell Therapy: Late-onset relapsing neurotoxicity after Brexucabtagene autoleucel associated with high chimeric antigen receptor T cells in cerebrospinal fluid. (Pubmed Central) - Aug 17, 2024
To our knowledge, this is the first case of late-onset, recurrent neurotoxicity. Moreover, an elevated level of cerebrospinal fluid CAR T cells was observed, which may suggest that the delayed neurotoxicity was primarily caused by the brain infiltration of CAR T cells rather than driven by cytokine-mediated neuroinflammation.
- | Rituxan (rituximab) / Roche
Retrospective data, Journal: Clinical and demographic characteristics of mucous membrane pemphigoid in India: A retrospective analysis. (Pubmed Central) - Aug 17, 2024
Rituximab was administered in 7 patients with severe or refractory disease...Visual complications are frequent in Indian MMP patients. A high index of suspicion is required for early diagnosis and appropriate treatment to prevent ocular complications.
- | Rituxan (rituximab) / Roche
Journal: Rituximab in the treatment of severe childhood pemphigus vulgaris accompanying phenylketonuria: A case report. (Pubmed Central) - Aug 17, 2024
A high index of suspicion is required for early diagnosis and appropriate treatment to prevent ocular complications. No abstract available
- | Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Journal, Combination therapy, PD(L)-1 Biomarker, IO biomarker: Significance of changes in tumor markers in patients treated with durvalumab plus tremelimumab combination therapy as a surrogate marker for tumor response to unresectable hepatocellular carcinoma. (Pubmed Central) - Aug 17, 2024
No abstract available The change in tumor markers is a more useful predicter of tumor response to Dur
- || Clinical, Journal: Drug Survival on First Biologic Therapy Among Late-Onset Rheumatoid Arthritis Patients Compared to Early-Onset Patients: A Population-Based Cohort Study. (Pubmed Central) - Aug 17, 2024
The change in tumor markers is a more useful predicter of tumor response to Dur Late-onset RA patients were treated with biologics to a lesser extent than early-onset patients, but no differences were observed in drug survival times at the first bDMARD between the two groups.
- || Polivy (polatuzumab vedotin-piiq) / Roche, Monjuvi (tafasitamab-cxix) / Incyte, Epkinly (epcoritamab-bysp) / Genmab, AbbVie
Clinical, Journal, CAR T-Cell Therapy: Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed/refractory large B-cell lymphoma. (Pubmed Central) - Aug 17, 2024
In this analysis, epcoritamab demonstrated significantly better response rates and overall survival rates than CIT, polatuzumab-based regimens, and tafasitamab-based regimens. No statistically significant differences in response rates or survival were found for epcoritamab compared with CAR T in R/R LBCL.
- || Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
Clinical, Retrospective data, Journal, HEOR, Real-world evidence, Real-world, Metastases: Comparative effectiveness analysis of survival with first-line palbociclib or ribociclib plus AI in HR?+?/HER2- advanced breast cancer (CEPRA study): preliminary analysis of real-world data from Thailand. (Pubmed Central) - Aug 17, 2024
No statistically significant difference in PFS, OS, and TTC was found in patients treated with AI combined with palbociclib or ribociclib. Longer follow-up and further prospective randomized head-to-head studies are warranted.
- | Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Journal: Variceal bleeding following treatment with atezolizumab plus bevacizumab in two patients with unresectable hepatocellular carcinoma. (Pubmed Central) - Aug 17, 2024
These findings suggest that ATZ/BV treatment may increase portal pressure. In conclusion, the administration of ATZ/BV to patients with LC and u-HCC necessitates careful management of EVs aggravation and rupture.